Westlake Village biotech firm MannKind reported more than tripling its revenue in the second quarter to $15 million and cut net losses by almost half to $12.4 million, or 7 cents per share. The results were largely in line with analyst expectations, driven by a 62 percent increase in sales over the previous second quarter…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.